3SBio Inc. is a biotechnology company. The Company is engaged in developing, manufacturing and marketing biopharmaceuticals. The Company's segment is the development, production, marketing and sale of biopharmaceutical products. The Company's core products include TPIAO, Yisaipu and EPIAO. TPIAO is a commercialized recombinant human thrombopoietin (rhTPO) product. Yisaipu is a tumor necrosis factor (TNF) a-inhibitor product. The Company has over 50 other products in oncology, nephrology, dermatology and other therapeutic areas. The Company has a pipeline of approximately 30 product candidates. It has approximately eight product candidates in oncology, including over four monoclonal antibody (mAb) therapeutics. It has various product candidates that target auto-immune diseases with unmet treatment needs, such as rheumatoid arthritis and refractory gout. It has approximately nine product candidates in nephrology, including over three next-generation erythropoiesis-stimulating agents.